二甲双胍、罗格列酮或联合应用对乳腺癌MCF-7细胞周期和凋亡的影响

Effect of metformin, rosiglitazone or their combination on the proliferation and apoptosis of human breast cancer cell MCF-7

目的观察二甲双胍单药、罗格列酮或联合应用对乳腺癌MCF-7细胞周期和凋亡的影响。方法用浓度为20 mmol/L二甲双胍(二甲双胍组)、100μmol/L罗格列酮(罗格列酮)及二甲双胍联合罗格列酮(联合用药组)处理MCF-7细胞48 h,分别采用MTT法、流式细胞术、Hoechst33258染色法观察细胞增殖、周期、凋亡情况。结果二甲双胍组、联合用药组的MCF-7细胞增殖被显著抑制,二甲双胍组、罗格列酮组、联合用药组阻滞MCF-7细胞于G0/G1期比例增加,S、G2/M期比例减少,二甲双胍组、罗格列酮组、联合用药组的细胞早期凋亡率分别为(15.3±1.09)%、(12.4±1.73)%、(17.2±1.63)%,与对照组比较差异有统计学意义(P<0.01)。结论单用二甲双胍或联合罗格列酮均能抑制MCF-7细胞的增殖,诱导其细胞周期停滞和凋亡。

Objective To investigate the effect of metformin, rosiglitazone or their combination on the proliferation and apoptosis of human breast cancer cell MCF-7. Methods MCF-7 cells were treated in 20 mmol/L metformin, 100 μmmol/L rosiglitazone or their combination for 48 h, respectively. MTT assay, flow cytometry and Hoechst33258 staining were used to observe the proliferation, cell cycle and apoptosis. Results The MCF-7 cell proliferation in Metformin Group and Combina- tion Group was significantly suppressed. The proportion of blocked MCF-7 cells in Metformin Group, Rosiglitazone Group and Combination Group was increased in G0/G1 phase and decreased in S, G2/M phase. Metformin Group, Rosiglitazone Group and Combination Group had early apoptosis rate of （15.3±1.09）%, （12.4± 1.73）% and （17.2±1.63）%, respectively, and there was statistical difference comparing with Control Group （P〈0.01）. Conclusion Single administration of metformin or its combination with rosiglitazone can prevent the proliferation of MCF-7 cells and induce the cell cycle arrest and apoptosis.